HJLIW - (Hancock Jaffe Laboratories Inc.)

 HJLIWのチャート


 HJLIWの企業情報

symbol HJLIW
会社名
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種   
概要 事業概要 --     Hancock Jaffe Laboratories, Inc. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. Its products include The Bioprosthetic Heart Valve, The CoreoGraft, and The Venous Valve. The company was founded by Norman Jaffe on December 22, 1999 and is headquartered in Irvine, CA.
本社所在地 --
代表者氏名
代表者役職名
電話番号
設立年月日 --
市場名 --
ipoyear 2018年
従業員数 -
url
nasdaq_url https://www.nasdaq.com/symbol/hjliw
adr_tso
EBITDA EBITDA ー
終値(lastsale) 0.54
時価総額(marketcap) 0
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 HJLIWのテクニカル分析


 HJLIWのニュース

   Hancock Jaffe Announces One Year Follow-up Data on Two Additional VenoValve Patients  2020/08/21 12:30:00 Yahoo Finance
VenoValve Patients Continue to Show Significant Improvement at One YearIRVINE, CA / ACCESSWIRE / August 21, 2020 / Hancock Jaffe Laboratories, Inc.
   Hancock Jaffe Laboratories : Receives Permission to Proceed with First-in-Human CoreoGraft Study | MarketScreener  2020/07/23 12:36:10 MarketScreener
July 23, 2020 Hancock Jaffe Receives Permission to Proceed with First-in-Human CoreoGraft Study Patient Selection to Begin Immediately for… | July 23, 2020
   Hancock Jaffe Laboratories : FY 2019 | MarketScreener  2020/03/18 22:18:13 MarketScreener
Identifying Performance Obligations and Licensing" and in May 9, 2016, the FASB issued ASU No. 2016-12, "Revenue from Contracts with Customers ", or ASU 2016-12. This update provides… | March 18, 2020
   Hancock Jaffe Laboratories : Annual report pursuant to Section 13 and 15(d) | MarketScreener  2020/03/18 21:08:23 MarketScreener
Identifying Performance Obligations and Licensing' and in May 9, 2016, the FASB issued ASU No. 2016-12, 'Revenue from Contracts with Customers ', or ASU 2016-12. This update provides clarifying… | March 18, 2020
   Hancock Jaffe Laboratories : FY 2019 | MarketScreener  2020/03/18 22:18:13 MarketScreener
Identifying Performance Obligations and Licensing" and in May 9, 2016, the FASB issued ASU No. 2016-12, "Revenue from Contracts with Customers ", or ASU 2016-12. This update provides… | March 18, 2020
   Hancock Jaffe Laboratories : Annual report pursuant to Section 13 and 15(d) | MarketScreener  2020/03/18 21:08:23 MarketScreener
Identifying Performance Obligations and Licensing' and in May 9, 2016, the FASB issued ASU No. 2016-12, 'Revenue from Contracts with Customers ', or ASU 2016-12. This update provides clarifying… | March 18, 2020
   Hancock Jaffe Laboratories : FY 2019 | MarketScreener  2020/03/18 22:18:13 MarketScreener
Identifying Performance Obligations and Licensing" and in May 9, 2016, the FASB issued ASU No. 2016-12, "Revenue from Contracts with Customers ", or ASU 2016-12. This update provides… | March 18, 2020
   Hancock Jaffe Laboratories : Annual report pursuant to Section 13 and 15(d) | MarketScreener  2020/03/18 21:08:23 MarketScreener
Identifying Performance Obligations and Licensing' and in May 9, 2016, the FASB issued ASU No. 2016-12, 'Revenue from Contracts with Customers ', or ASU 2016-12. This update provides clarifying… | March 18, 2020

 関連キーワード  (― 米国株 HJLIW Hancock Jaffe Laboratories Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)